December 20, 2019 Plenty of choice remains for buyers of gene therapy Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
December 12, 2019 Ash 2019 winners and losers Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
